Thursday, February 02, 2006

MedImmune Tanks

What a pathetic showing for MedImmune (MEDI) out there today.

The makers of flu vaccine flu mist posted a fourth-quarter net loss, citing heavy acquisition costs which pounded what they thought would be strong sales from respiratory drug Synagis.

What a joke that was.

The company posted a net loss of $22 million compared with a profit of $51 million a year ago.

Back on September 8th, we said this stock was dead money since it was priced on a hyped up flu scare:
Another 3 million doses will come from -- you guessed it -- MedImmune, whose FluMist nasal spray has been a hit with kids but less so with shareholders.

FluMist is currently approved only for ages 5 to 49 - the group with the lowest vaccination rate. Second, the price tag is a problem investors are overlooking: FluMist costs at least 2 times what a simple $10 or $20 needle injection costs.

The CDC estimates 36,000 people a year die from influenza. However, since a deadly combination of government regulation and pricing pressures put the once booming vaccine industry on flatline, the companies have been eking out whatever small profits they can.
MedImmune has $28 written all over it.

About Us | In the News | Management | Contact Us | Archive | Premium Membership | Terms of Use | Privacy Policy | Careers | FAQ

All quotes are 15 minutes delayed. Copyright © 2006 by Catablast! Media Group LLC, part of the SeekingAlpha network. Web Design by Synexio Systems. All Rights Reserved.